This grant information is supplied by the University of Michigan. Only grants received while at the University of Michigan are included.
1/6/2014 - 11/30/2018
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF FULVESTRANT (FASLODEX?) WITH OR WITHOUT PD-0332991 (PALBOCICLIB) GOSERELIN IN WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY
1/1/2014 - 12/31/2019
Sponsor: Pfizer Incorporated sourced funding through Parexel International Corp.
1/1/2014 - 12/31/2016
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
12/13/2013 - 10/31/2020
Sponsor: Janssen Research and Development, LLC
12/13/2013 - 10/14/2020
Sponsor: INC Research
A PHASE Ib, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOLOGY OF GDC-0068 IN COMBINATION WITH DOCETAXEL, FLUOROPYRIMIDINE PLUS OXALIPLATIN, PACLITAXEL, OR ENZALUTAMIDE IN PATIENTS WITH ADVANCED SOLID TUMORS
12/10/2013 - 11/30/2018
Sponsor: Genentech, Inc. sourced funding through PPD, Inc.
Daniel Hayes; Costanza Paoletti
Significance of Circulating Tumor Cells in metastatic triple negative breast cancer: Results of an open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 (DR5) Tigatuzumab (TBCRC 019)
12/10/2013 - 12/14/2013
Sponsor: University of Texas San Antonio
Laurence Baker; Rama Jasty; Rajen Mody
12/1/2013 - 11/30/2014
Sponsor: St. Baldrick's Foundation
11/22/2013 - 9/30/2018
Sponsor: Eli Lilly and Company
A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of BMN 673 versus Physician?s Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer, Who Have Received No More than 2 Prior Chemotherapy Regimens for Metastatic Disease
11/22/2013 - 10/31/2017
Sponsor: BioMarin Pharmaceutical Inc.
11/20/2013 - 11/19/2018
Sponsor: Genentech, Inc. sourced funding through INC Research
A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA?) 300 mg in Patients with Papillary or Poorly Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
11/18/2013 - 9/2/2018
Sponsor: AstraZeneca PLC
11/15/2013 - 10/31/2017
Sponsor: Novartis Pharma, Inc.
Suman Sood; Thomas Wakefield; Daniel Clauw; Daniel Myers
11/15/2013 - 11/14/2016
11/15/2013 - 7/31/2015
Sponsor: Sanofi sourced funding through Ohio State University
11/5/2013 - 8/31/2019
Sponsor: Seattle Genetics, Inc. sourced funding through Pra International
11/1/2013 - 8/31/2020
Sponsor: Medpace, Inc.
10/29/2013 - 9/30/2018
10/25/2013 - 8/31/2020
Sponsor: Medivation, Inc.
10/11/2013 - 8/31/2018
Sponsor: Merck Sharp and Dohme Research Labs